HELP Cybin Inc.
Company Analysis
Latest News
🟢 HELP is trading 5.02% up today on financing and pipeline momentum
HELP is trading 5.02% up at $6.80 following Cybin’s recent financing and pipeline momentum. • The move is largely attributed to the company's $50 million...
Cybin Inc. Q1 2026 Earnings Preview: What Analysts Expect on June 29, 2026
Analysts expect Cybin Inc. to report a consensus EPS loss of $1.04 on zero revenue, with the stock currently priced at $4.85 compared to a $49.05 average...
🟢 HELP is trading 5.15% up today after closing a $50M offering for Phase 3 trials
HELP is trading 5.15% up at $6.33 after Cybin/Helus Pharma closed a $50 million share offering to fund late-stage depression-trial work. • The capital...
Helus Pharma Secures $50 Million, Funding Phase 3 Depression Trials
Helus Pharma, the operating name for Cybin Inc., closed its public offering of 10,309,280 common shares. The company sold the shares at US$4.85 each to raise...
🔴 HELP is trading 6.2% down today after a $50 million equity offering and recent rally
HELP is trading 6.2% down at $5.65 in pre-market following a $50 million underwritten equity offering and profit-taking after a sharp multi-day rally. • The...
🟢 HELP is trading 11% up today after $50M equity offering to fund drug pipeline
HELP is trading 11% up at $5.65 after announcing a $50 million underwritten public offering of common shares to advance its mental health drug pipeline. • The...
🟢 HELP soars 5.7% after announcing US$50 million underwritten offering
• Helus Pharma (HELP) announced a US$50 million underwritten public offering of 10,309,280 common shares priced at $4.85 per share on June 24, 2026. • The...
🟢 HELP makes sharp 10.1% jump
HELP is trading at $5.34, up 10.1% versus the comparison close of $4.85 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 HELP is trading 9.3% up today after pricing $50M offering to fund Phase 3 trial
HELP is trading 9.3% up now at $5.30 after the company priced a $50 million underwritten public offering at $4.85 per share. • The capital raise will fund...
Helus Pharma Raises $50 Million Selling Stock at a Discount — But Can the Cash Get Its Depression Drug Across the Finish Line?
Shares shifted as Helus Pharma (Nasdaq: HELP), formerly known as Cybin, priced a US$50 million underwritten public offering just hours before its lead...
🟢 HELP makes sharp 10.7% jump
HELP is trading at $5.37, up 10.7% versus the comparison close of $4.85 during pre-market. This is a price-movement alert; no separate company-specific...
🟢 HELP is trading 9.1% up today after pricing a $50M public offering
HELP is trading 9.1% up at $5.29 in pre-market action after announcing a $50 million underwritten public offering priced at $4.85 per share. • The financing...
🟢 Cybin Inc. is trading 5.9% up today after analysts issued a 'Strong Buy' consensus rating
Cybin Inc. is trading 5.9% up today at $4.54 following a 'Strong Buy' consensus rating from analysts as of June 17, 2026. • Analysts have set a price target...
🟢 Cybin Inc. is trading 5.7% up today amid a broad market rebound
Cybin Inc. is trading at $4.28 (+5.68%) as the stock gains momentum following a broader market recovery. • Major U.S. indexes are trading higher, providing...
🟢 Cybin Inc. is trading 5.7% up today tracking a broad market rebound
Cybin Inc. is trading 5.7% up at $4.09 as it tracks a broad market rebound and recovers from several consecutive down sessions. • Major U.S. indices are...
🟢 Cybin Inc. is trading 5.4% up today as broader market futures rise
Cybin Inc. is trading 5.4% up at $4.08 in pre-market, rebounding from recent weakness and tracking broader market gains. • The stock is recovering from...
Helus Pharma Plummets 50% on CEO Exit, Awaiting Major Depression Data
Helus Pharma (formerly Cybin Inc.) shares have dropped more than 50% following the unexpected departure of CEO Michael Cola in April 2026. Co-founder and...
🔴 Cybin Inc. is trading 5.9% down today amid a broad market risk-off session
Cybin Inc. is trading at $3.77 (-5.86%) as the stock extends its recent slide during a broad market risk-off session where speculative growth names are under...
🟢 Cybin Inc. is trading 6% up today on a technical rebound after recent weakness
Cybin Inc. is trading 6% up at $4.25 in pre-market sessions as the stock stages a technical rebound following recent downward pressure. • The move appears to...
🟢 Cybin Inc. is trading 6% up today as it rebounds from recent weakness
Cybin Inc. is trading 6% up at $4.25 in pre-market, rebounding from recent weakness following several consecutive down sessions last week. • The move lacks a...